Holen Sie sich die Stockscreener-App
6.885
0.51%
-0.035
Handel nachbörslich:
6.89
0.005
+0.07%
Kyntra Bio Inc Aktie (KYNB) Neueste Nachrichten
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Kyntra Bio Charts a New Course in Oncology - AD HOC NEWS
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
KYNB Stock Price, Forecast & Analysis | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
KYNB: Kyntra Bio IncFull Company Report - Zacks Investment Research
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FibroGen Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
FGEN Stock Price, News & Analysis - Stock Titan
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FGEN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen, Inc. Announces Cessation of Christine L. Chung as Senior Vice President, China Operations - marketscreener.com
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
Kyntra Bio Inc (KYNB) Stock Price Quote Today & Current Price Chart - Capital.com
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - marketscreener.com
FibroGen: Q2 Earnings Snapshot - marketscreener.com
FibroGen to Report Second Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference - marketscreener.com
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen regains rights to anemia drug from AstraZeneca - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results - marketscreener.com
Fibrogen, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? - The Motley Fool
Stifel downgrades FibroGen to hold, says it's lost confidence in lead drug (FGEN) - Seeking Alpha
FibroGen stock down as trial for lung disease drug fails - Seeking Alpha
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else - Citeline News & Insights
Meet Ananth Narayanan, Ex-Myntra CEO, Mensa Brands founder: Know about his journey, education & family - The Financial Express
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - GlobeNewswire
FibroGen stock falls ~10% after roxadustat fails phase 3 trial for anemia - Seeking Alpha
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still Haunts It (NASDAQ:FGEN) - Seeking Alpha
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating - marketscreener.com
Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook - simplywall.st
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference - marketscreener.com
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug? - The Motley Fool
Here's Why FibroGen Stock Is Plunging Today - The Motley Fool
FibroGen, Inc. Appoints John Hunter as Chief Scientific Officer - marketscreener.com
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):